Publicaties betreffende BOOG studies
d.d. november 2017

Inhoud

BOOG 2001-01 / TEAM 2
BOOG 2001-02 / AMAROS 11
BOOG 2002-02 / HERTAX 11
BOOG 2002-04 / HERA 12
BOOG 2003-02 / CALOR 14
BOOG 2003-04 / BCP 15
BOOG 2004-01 / Young Boost (CKTO 2003-13) 15
BOOG 2004-02 / TBP 16
BOOG 2005-02 / MATADOR 17
BOOG 2005-03 / MINDACT 17
BOOG 2006-01 / DATA 19
BOOG 2006-02 / OMEGA 19
BOOG 2006-03 / SUPREMO 20
BOOG 2006-04 / TEAM-II 21
BOOG 2006-05 / IDEAL 21
BOOG 2006-06 / ATX 22
BOOG 2006-07 / MIRROR 24
BOOG 2007-01 / ALLTO 25
BOOG 2007-02 / INTENS 25
BOOG 2008- 01 / 2-2-6 G-CSF 26
BOOG 2008-02 / A6181099 (SUTENT) 27
BOOG 2008-03 / HAT 27
BOOG 2009-01 / IRMA 27
BOOG 2009-02 / SNARB 27
BOOG 2009-03 / DCIS 28
BOOG 2009-04 / Male Breast cancer 28
BOOG 2009-05 / BOLERO-2 29
BOOG 2010-01 / NEO-ZOTAC 30
BOOG 2010-03 / RAPCHEM 33
BOOG 2010-05 / SUBMIT 33
BOOG 2012-01 / BALLET 33
BOOG 2012-02 / SafeHer 34
BOOG 2012-03 / TRAIN-2 334
BOOG 2013-04 / DIRECT 34
BOOG 2013-06 / BIOMARKER EVEROLIMUS 34
BOOG 2014-01 / MONALEESA-2 35
BOOG 2014-03 / OLYMPIA 35
BOOG 2014-04 / LORD 35
BOOG 2014-05 / INFLAME 36
Patientenparticipatie 36

Titel artikel
Naam AB, Naam AC, Naam AD, etc
(Publicatiejaar) Tijdschrift van publicatie en evt paginanrs

BOOG 2001-01 / TEAM

TEAM

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine.
Bayani J, Yao CQ, Quintayo MA, Yan F, Haider S, D'Costa A, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Boutros PC, Bartlett JMS.
NPJ Breast Cancer. 2017 Feb 15;3:3.

The influence of insulin-like Growth Factor-1-Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis.
Engels CC, de Glas NA, Sajet A, Bastiaannet E, Smit VT, Kuppen PJ, Seynaeve C, van de Velde CJ, Liefers GJ.
Mol Oncol. 2016 Apr;10(4):509-16.

Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial.
Derks MG, de Glas NA, Bastiaannet E, de Craen AJ, Portielje JE, van de Velde CJ, van Leeuwen FE, Liefers GJ.
Oncologist. 2016 Aug;21(8):946-53.

Variation in the *ESR-1* gene as a prognostic marker in early breast cancer survival.
Danny Houtsma, Stefanie de Groot, Tahar van der Straaten, Renee Baak-Pablo, Cock J.H. van der Velde, Henk-Jan Guchelaar, Hans Gelderblom
ASCO 2014

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW.
Arch Pathol Lab Med. 2016 Jan;140(1):66-74.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde CJH, Pan H, Peto R, Davies C, Gray R.
Lancet. 2015 Oct 3;386(10001):1341-52.

S4-06. HER2 status as predictive marker for AI vs Tam benefit: a TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS et al.
(2015) SABCS

P2-08-29. Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial.
Bayani J et al.
(2015) SABCS

Does androgen receptor (AR) expression impact on residual risk? A TEAM pathology study

John MS Bartlett[1], Cassandra L Brookes[2], Fu J Yan[1], Mary Anne Quintayo[1], Jane Bayani[1], Jane Starczynski[3], Cornelis JH van de Velde[4], Annette Hasenburg[5], Dirk G Kieback[6], Christos Markopoulos[7], Luc Dirix[8], Caroline Seynaeve[9] and Daniel W Rea[2]
SABCS 2014, publication number P4-11-05

PIK3CA Mutations Are Linked to PgR Expression: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) Pathology Study.
Sabine VS, Crozier C, Drake C, Piper T, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Bartlett JMS
SABCS 2012

Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
DBY Fontein, D Houtsma, ETM Hille, C Seynaeve, H Putter, E Meershoek-Klein Kranenbarg, HJ Guchelaar, H Gelderblom, LY Dirix,R Paridaens, JMS Bartlett, JWR Nortier, CJH van de Velde, on behalf of the Dutch TEAM steering committee.
(2012) Ann Oncol, Aug 2 [Epub ahead of print]

Influence of semi-quantitative estrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – a TEAM study analysis.
W van de Water and DBY Fontein, JGH van Nes, JMS Bartlett, ETM Hille, H Putter, T Robson, GJ Liefers, RMH Roumen, C Seynaeve, LY Dirix, R Paridaens, E Meershoek-Klein Kranenbarg, JWR Nortier, CJH van de Velde
(2012) European Journal of Cancer, accepted July 2012

Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
van de Water W, Markopoulos C, van de Velde CJH, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, de Craen AJ, Hille ETM, Bastiaannet E,Hadji P, Westendorp RG, Liefers GJ, Jones SE.
JAMA.
(2012) 2012 Feb 8;307(6):590-7.

Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.
van de Water W, Bastiaannet E, Hille ETM, Meershoek-Klein Kranenbarg E, Putter H, Seynaeve CM, Paridaens R, de Craen AJ, Westendorp RG,Liefers GJ, van de Velde CJH.
(2012) Oncologist. ;17(1):55-63. Epub 2011 Dec 30.

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors – a TEAM trial analysis.
Duveken BY Fontein, Peyman Hadji, Caroline Seynaeve, Annette Hasenburg, Robert Paridaens, Jean-Michel Vannetzel, Christos Markopoulos, Stephen E Jones, Daniel Rea, Cornelis JH van de Velde.
(2012) Presentatie ESSO 2012, 19-21 september, Valencia

Heterogeneous HER2 Gene Amplification Impact on Patient Outcome and a Clinically Relevant Definition.
Bartlett AI, Starcyznski J, Robson T, MacLellan A, Campbell FM, van de Vekle CJH, Hasenburg A, Markopoulos C, Seynaeve C, Rea D, Bartlett JMS
*(2011) American Journal of Clinical Pathology **136** (2): 266-274*

Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial.
Bartlett JMS, Brookes CL, Robson T, van de Velde CJH, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback DG, Putter H, Markopoulos C, Meershoek-Klein-Kranenbarg E,

Mallon EA, Dirix L, Seynaeve C, Rea D
*(2011) Journal of Clinical Oncology **29** (12): 1531-1538*

Efficacy of endocrine therapy regimens in major histological subtypes of breast cancer – TEAM study analysis.
Fontein DBY, van de Water W, Bartlett JMS, Liefers GJ, Markopoulos C, Seynaeve C, Meershoek-Klein-Kranenbarg E, Rea D, Jones SE, Hille ETM, Putter H, Roumen RMH, Nortier JWR, van de Velde CJH
(2011) Ejc Supplements

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.
Hadji P, Asmar L, van Nes JGH, Menschik T, Hasenburg A, Kuck J, Nortier JWR, van de Velde CJH, Jones SE, Ziller M
*(2011) Journal of Cancer Research and Clinical Oncology **137** (6): 1015-1025*

Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis.
Hadji P, Asmar L, van Nes JG, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, Van der Velde C, Ziller M
*(2011) Breast **20** S70*

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Hozumi Y, Suemasu K, Takei H, Aihara T, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y
*(2011) Annals of Oncology **22** (8): 1777-1782*

Age specific competing mortality in breast cancer patients – a TEAM study analysis.
Markopoulos C, van de Water W, Putter H, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, van de Velde CJH, Jones SE
(2011) Ejc Supplements

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Van de Velde CJH, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ETM, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Burdett JMS, Jones SE
*(2011) Lancet **377** (9762): 321-331*

Specific Adverse Events and Outcome in Hormone Receptor Positive Breast Cancer Patients on Endocrine Therapy – a TEAM Study Analysis.
Van de Water W, Hille ETM, Hadji P, Markopoulos C, Seynaeve C, Hasenburg A, Dirix L, Rea D, Jones SE, van de Velde CJH
(2011) Ejc Supplements

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy.
Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y
*(2010) Oncology **79** (5-6): 376-381*

Is 5-50% of Amplified Cells a Suitable Cut Off To Define Heterogeneous Amplification of the HER2 Oncogene?
Bartlett AI, Starcyznski J, Robson T, van de Velde CJH, Hasenburg A, Markopoulos C, Rea DW, Campbell FM, Bartlett JMS
*(2010) Cancer Res **70** (24 Suppl)*

Final Results of a Prospectively Planned Biomarker Analysis: HER1-3 as Predictive Markers of Benefit from Early Treatment with Aromatase Inhibitors Versus Tamoxifen in the TEAM Pathology Sub-Study.
Bartlett JMS, Brookes CL, van de Velde CJH, Stocken D, Campbell FM, Hasenburg A, Kay C, Kieback D, Markopoulos C, Meershoek-Klein-Kranenbarg E, Mallon EA, Dirix L, Robson T, Seynaeve C, Rea DW
*(2010) Cancer Res **70** (24 Suppl)*

Mammostrat® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study.
Bartlett JMS, Bloom KJ, Goldstein NS, van de Velde CJH, Ross DT, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Robson T, Seynaeve C, Rea DW
*(2010) Cancer Res **70** (24 Suppl)*

An Integration of Biological and Pathological Marker Panel in the TEAM Pathology Sub-Study: The Impact of Different Parameters on Risk Estimation of Relapse at Both 2.75 and 5 Years.
Bartlett JMS, Stocken D, van de Velde CJH, Brookes CL, Robson T, Hasenburg A, Hille ETM, Kieback D, Markopoulos C, Mallon EA, Dirix L, Campbell FM, Seynaeve C, Rea DW
*(2010) Cancer Res **70** (24 Suppl)*

A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors.
Bartlett JMS, Gustavson M, Stocken D, Rimm D, Christiansen J, van de Velde CJH, Hasenburg A, Kieback D, Putter H, Brookes C, Markopoulos C, Dirix L, Robson T, Seynaeve C, Dolled-Filhart M, Jones C, Graves L, McGuire J, Rea D
*(2010) Cancer Res **70** (24 Suppl)*

Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
Dezentje VO, van Schaik RH, Vletter-Bogaartz JM, Wessels JA, Hille ETM, Seynaeve C, van de Velde CJH, Nortier JWR, Gelderblom H, Guchelaar HJ
*(2010) Journal of Clinical Oncology **28** (15s)*

Effects of Exemestane or Tamoxifen on Bone Health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial: A Meta-Analysis.
Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van de Velde CJH, Ziller M
*(2010) Cancer Res **70** (24 Suppl)*

Effects of Exemestane Or Tamoxifen on Bone Health Within the Tamoxifen Exemestane Adjuvant Multinational (Team) Trial: A Meta-Analysis.
Hadji P, Asmar L, van Nes J, Menschik T, Hasenburg A, Kuck J, Nortier H, Jones S, van de Velde C, Ziller M
*(2010) Annals of Oncology **21** 81-82*

Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer.
Hasenburg A, van de Velde CJH, Seynaeve C, Rea DW, Vannetzel J, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Jones SE
*(2010) Ejc Supplements **8** (3): 62*

TEAM-studie: gelijkwaardige overleving door zowel monotherapie als sequentiële therapie.
Hille ETM
*(2010) Oncologie Up-to-Date **1** (1): 3-4*

Adjuvante endocriene therapie met exemestaan of de sequentie van tamoxifen, gevolgd door exemestaan bij postmenopauzale vrouwen met hormoongevoelige borstkanker.

Hille ETM, Seynaeve C, Nortier JWR, van de Velde CJH
*(2010) Nederlands Tijdschrift voor Oncologie **7** (7): 304-309*

The effect of exemestane and anastrozole on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: final results of 3 years after randomization of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.
Hozumi Y, Aihara T, Suemasu N, Takei H, Takehara M, Masuda N, Ohashi Y
*(2010) Ejc Supplements **8** (3): 165*

Competing Causes of Mortality vs. Breast Cancer Mortality at 5-Years among 9766 Postmenopausal Women with Hormone Receptor Positive Early Breast Cancer Treated on the TEAM Study of Adjuvant Hormonal Therapy.
Jones, S. E., Putter, H., Hasenburg, A., van de Velde, C. J. H., Rea, D. W., Vannetzel, J. M., Paridaens, R., Markopoulos, C., Hozumi, Y., and Seynaeve C.
(2010) Cancer Res 70[24 Suppl]. 15-12-2010. Ref Type: Internet Communication

Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy.
Kieback DG, Harbeck N, Bauer W, Hadji P, Weyer G, Menschik T, Hasenburg A
*(2010) Gynecologic Oncology **119** (3): 500-505*

Distant Recurrences at Median of 5-Years Among 9.779 Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Treated on the Team Trial of Adjuvant Endocrine Therapy.
Nortier H, Hille E, Rea D, Seynaeve C, Hasenburg A, Vannetzel J, Dirix L, Markopoulos C, van de Velde C, Jones S
*(2010) Annals of Oncology **21** 78*

Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial.
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, de Velde CJV, van Dam FS, Schagen SB
*(2010) Journal of Clinical Oncology **28** (8): 1294-1300*

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
Schilder CMT, Seynaeve C, Linn SC, Boogerd W, Beex LVAM, Gundy CM, Nortier JWR, van de Velde CJH, Van Dam FSAM, Schagen SB
*(2010) Critical Reviews in Oncology Hematology **76** (2): 133-141*

The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer (BC) Patients; Exploratory Analysis from the TEAM Study.
Seynaeve C, Hille ETM, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier HWR, van Nes JGH, Dirix L, van de Velde CJH
*(2010) Cancer Res **70** (24 Suppl)*

Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
Van de Velde CJH, Verma S, van Nes JGH, Masterman C, Pritchard KI
*(2010) Cancer Treatment Reviews **36** (1): 54-62*

Discontinuation during Tamoxifen in the Sequential Arm of the TEAM Trial of Adjuvant Endocrine Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer: The Effect of IES Results and Subsequent Therapy.
Van de Velde CJH, Hille ETM, Rea D, Seynaeve C, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Kieback DG, Asmar L, Smeets J, Nortier JWR, Hadji P, Bartlett JMS, Putter H,

Jones SE
*(2010) Cancer Res **70** (24 Suppl):*

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.
Van Nes JGH, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJH
*(2010) British Journal of Surgery **97** (5): 671-679*

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Van Nes JGH, Seynaeve C, Maartense E, Roumen RMH, de Jong RS, Beex LVAM, Meershoek-Klein-Kranenbarg E, Putter H, Nortier JWR, van de Velde CJH
*(2010) Annals of Oncology **21** (5): 974-982*

Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients.
Voskuil DW, van Nes JGH, Junggeburt JMC, van de Velde CJH, Van Leeuwen FE, De Haes JCJM
*(2010) Annals of Oncology **21** (10): 2094-2101*

The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy.
Bartlett JMS, Brookes C, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Quintayo MA, Lyttle N, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Meershoek-Klein-Kranenbarg E, Paridaens R, Seynaeve C, Mallon EA, Rea DW
*(2009) Cancer Research **69** (24): 503S*

Estrogen and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational (TEAM) trial.
Bartlett JMS, Brookes CL, de Velde CJHV, Billingham LJ, Hasenberg A, Markopoulos C, Mallon EA, Paridaens R, Seynaeve C, Rea DW
*(2009) Ejc Supplements **7** (2): 264*

A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.
Bartlett JMS, Brookes CL, Billingham LJ, Campbell FM, Grant M, Hasenburg A, Hille ETM, Kay C, Kieback D, Markopoulos C, Meershoek-Klein-Kranenbarg E, Mallon EA, Paridaens R, Robson T, Seynaeve C, van de Velde CJH, Rea D
*(2009) Cancer Research **69** (2): 83S*

Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.
Bartlett JMS, Rimm D, Brookes CL, Dolled-Filhart M, Robson T, van de Velde CH, Billingham LJ, Campbell FM, Hasenburg A, Hille ETM, Kieback D, Putter H, Markopoulos C, Christiansen J, Gustavson M, Mallon EA, Kranenburg EMK, Parideans R, Seynaeve C, Rea DW
*(2009) Cancer Research **69** (24): 660S-661S*

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer.
Dezentje VO, Guchelaar HJ, Nortier JWR, van de Velde CJH, Gelderblom H
*(2009) Clinical Cancer Research **15** (1): 15-21*

Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: The TEAM Trial Experience.
Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JMS
*(2009) Histopathology **55** (5): 587-593*

The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A
*(2009) Breast **18** (3): 159-164*

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.
Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A
*(2009) Annals of Oncology **20** (7): 1203-1209*

Bone effects of exemestane vs. tamoxifen within the TEAM trial: results of a prospective randomized bone sub study.
Hadji P, Ziller M, Kieback D, Dornoff W, Tessen HW, Kuck J, Hasenburg A
*(2009) Cancer Research **69** (2): 149S*

Eerste resultaten van de TEAM-studie.
Hille ETM
*(2009) Oncology News International **3** (1): 3-5*

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
Jones SE, Seynaeve C, Hasenburg A, Rae D, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Kieback D, Asmar L, Smeets J, Urbanski R, Bartlett JMS, van de Velde CJH
*(2009) Cancer Research **69** (2): 67S*

Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy.
Markopoulos C, Polychronis A, Dafni U, Koukouras D, Zobolas V, Tzorakoleftherakis E, Xepapadakis G, Gogas H
*(2009) Annals of Oncology **20** (1): 49-55*

Aromatase inhibitors in the management of early breast cancer: The TEAM trial.
Markopoulos C
*(2009) Ejso **35** (3): 333*

Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
Rea D, Hasenburg A, Seynaeve C, Jones SE, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Putter H, Hille E, Asnar L, Urbanski R, van de Velde CH, Bartlett JMS, Smeets J, Kieback DG
*(2009) Cancer Research **69** (24): 487S*

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study.
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Huizenga HM, Nortier JW, van der Velder CJ, van Dam FS, Schagen SB
*(2009) Cancer Research **69** (2): 146S*

Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, van Dam FS, Schagen SB
*(2009) Acta Oncologica **48** (1): 76-85*

Different effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the Dutch TEAM neuropsychological side study.
Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB
*(2009) Ejc Supplements **7** (2): 264*

Tamoxifen and exemestane adjuvant multinational (TEAM) trial; findings from the Dutch/belgian subset.
Seynaeve C, van de Velde CJH, Maartense E, Roumen RMH, Nortier JWR, Hille ETM, van Nes JGH, Putter H, Paridaens R, Dirix LY
*(2009) Ejc Supplements **7** (2): 300*

Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
Van de Velde C, Seynaeve C, Hasenburg A, Rea D, Vannetzel JM, Paridaens R, Markopoulos C, Smeets J, Nortier JWR, Jones SE
*(2009) Ejc Supplements **7** (3): 1*

Patterns of care in postmenopausal early breast cancer patients participating in the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study: variations in locoregional therapy between different countries.
Van Nes JGH, Seynaeve C, Jones S, Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Markopoulos C, Meershoek-Klein-Kranenbarg E, van de Velde CJH
*(2009) Ejc Supplements **7** (2): 301*

Effect of exemestane on bone turnover markers and bone mineral density (BMD): 2 year results of the Dutch/Belgian Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Van Nes JGH, Papapoulos SE, Braun JJ, Dirix L, Putter H, Zwaan RE, Ballieux BEP, van Rongen I, van de Velde CJH, Seynaeve C, Nortier JWR
*(2009) Cancer Research **69** (2): 152S-153S*

Quality of life in relation to hormonal treatment of postmenopausal women in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Van Nes JGH, Voskuil DW, van Leeuwen RE, Junggeburt JMC, De Haes HCJM, van de Velde CJH
*(2009) Cancer Research **69** (2): 69S*

Physical activity to maintain quality of life in breast cancer survivors in the Dutch Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Voskuil DW, van Nes JG, Junggeburt JM, Van Leeuwen FE, van de Velde CJ, de Haes HC
*(2009) Cancer Research **69** (2): 277S*

TEAM trial and substudies confirm the efficacy and safety of exemestane in women with early hormone-sensitive breast cancer.
Jones S, Coombes RC, Schilder CTM, Voskuil DW, van Nes J, Hadji P, Bartlett J. *(2008) Highlights from 31st SABCS)*

Clinical implications of CYP2D6 genotyping on tamoxifen treatment in breast cancer.
Dezentje VO, Nortier JWR, Guchelaar HJ, van de Velde CJH, Gelderblom H.
*(2008) Ejc Supplements **6** (7): 56*

Endometrial safety of cross-over treatment with tamoxifen followed by exemestane.
Kieback DG, Harbeck N, Bauer W, Hadji P, Weyers G, Hasenburg A
*(2008) Ejc Supplements **6** (7): 198*

The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.
Ihara T, Hozumi Y, Suemasu K, Takei H, Takehara M, Osumi S, Saito T, Masuda N, Ohashi Y
*(2007) Breast Cancer Research and Treatment **106** S114*

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant Multicenter trial substudy.
Jones SE, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum JL, Brooks R, Hartung NL, Negron AG, Richards DA, Rivera R, Holmes FA, Chittoor S, Whittaker TL, Bordelon JH, Ketchel SJ, Davis JC, Ilegbodu D, Kochis J, Asmar L
*(2007) Journal of Clinical Oncology **25** (30): 4765-4771*

The effect of exemestane, anastrozole and tamoxifen on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of NSAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study.
Hozumi Y, Suemasu K, Takehara M, Takei H, Aihara T, Tamura M, Ohsumi S, Masuda N, Saito T, Mukai H, Ohashi Y
*(2006) Breast Cancer Research and Treatment **100** S188*

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: Preliminary results of the TEAM Greek sub-study.
Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H
*(2005) Breast Cancer Research and Treatment **93** (1): 61-66*

The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study.
Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Papadiamantis J, Bafaloukos D, Misitzis J, Michailidou A, Gogas H
*(2004) Journal of Clinical Oncology **22** (14): 76S*

The effect of exemestane (Aromasin (R)) on the lipidemic profile of breast cancer patients: preliminary results of the TEAM trial Greek sub-study.
Markopoulos C, Polychronis A, Farfarelos C, Zobolas V, Bafaloukos D, Papadiamantis J, Misitzis J
*(2003) Breast Cancer Research and Treatment **82** S105*

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Engels CC, Charehbili A, van de Velde CJH, Bastiaannet E, Sajet A, Putter H, van Vliet EA, van Vlierberghe RL, Smit VT, Bartlett JM, Seynaeve C, Liefers GJ, Kuppen PJ.
Breast Cancer Res Treat. 2015 Feb;149(3):587-96.

Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.
Fontein DB, Klinten Grand M, Nortier JW, Seynaeve C, Meershoek-Klein Kranenbarg E, Dirix LY, van de Velde CJH, Putter H.
Ann Oncol. 2015 Jun;26(6):1254-62.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).
Eur J Cancer. 2017 Jul;79:129-138

Adjuvant tamoxifen and exemestane in postmenopausal early breast cancer: ten-year analysis of the TEAM trial.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Meershoek-Klein Kranenbarg E, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Smeets J, Dirix LY, Paridaens R, van de Velde CJH.
Lancet Oncology. 2017, Jul 18 on-line

BOOG 2001-02 / AMAROS

Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: identification rate and nodal outcome.
Donker M, Straver ME, van Tienhoven G, van de Velde CJ, Mansel RE, Litière S, Werutsky G, Duez NJ, Orzalesi L, Bouma WH, van der Mijle H, Nieuwenhuijzen GA, Veltkamp SC, Helen Westenberg A, Rutgers EJ.
Eur J Cancer. 2013 Jun;49(9):2093-100.

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023)
E. J. Rutgers, M. Donker, M. E. Straver, Ph. Meijnen, C. J. H. van de Velde, R. E. Mansel, H. Westenberg, L. Orzalesi, W.H. Bouma, H. van der Mijle, G. A. P. Nieuwenhuijzen, S. C. Veltkamp, L. Slaets, C.G. M. Messina, N. J. Duez, C. Hurkmans, J. Bogaerts, and G. van Tienhoven
Oral presentation **ASCO Abstract # LBA1001**

Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Duez N, Cataliotti L, Klinkenbijl JH, Westenberg HA, van der Mijle H, Snoj M, Hurkmans C, Rutgers EJ.
Ann Surg Oncol. 2010 Jul;17(7):1854-61.

Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.
Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, Demonty G, Duez N, Cataliotti L, Klinkenbijl J, Westenberg HA, van der Mijle H, Hurkmans C, Rutgers EJ.
J Clin Oncol. 2010 Feb 10;28(5):731-7.

Analyses met betrekking tot de technische aspecten, gebaseerd op de eerste 2000 patiënten zijn (met toestemming van de IDMC)
ASCO Breast Cancer Symposium (Washington DC, september 2008) en 31st San Antonio Breast Cancer Symposium in december 2008.

Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run.
Hurkmans CW, Borger JH, Rutgers EJ, van Tienhoven G; EORTC Breast Cancer Cooperative Group; Radiotherapy Cooperative Group.
Radiother Oncol. 2003 Sep;68(3):233-40.

BOOG 2002-02 / HERTAX

Randomized phase II study comparing efficacy and safety of combination therapy trastuzumab and docetaxel versus sequential therapy of trastuzumab followed by docetaxel alone at progression as first line chemotherapy in patients with HER2-positive metastatic breast cancer: HERTAX trial.
P. Hamberg, M. M.E.M. Bos, H.J.J. Braun, J.M.L. Stouthard, G. A. van Deijk, F. L.G. Erdkamp, I.N. van der Stelt-Frissen, M. Bontenbal, G.J. M. Creemers, J.E.A. Portielje, J.F.M. Pruijt, O.J.L. Loosveld, W.M. Smit, E.W. Muller, P. I.M. Schmitz, C.Seynaeve, J.G.M. Klijn
Clinical Breast Cancer April 2011 p 103-113

Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study).

M. Bontenbal, C. Seynaeve, J. Stouthard, M. Bos, H. Braun, F. Erdkamp, G. van Deijk, P. Schmitz, I. van der Stelt-Frissen, P. Hamberg, J. Klijn
J Clin Oncol 26: 2008 (May 20 suppl; abstr 1014) Oral presentation

Sequential Rx effective, less toxic in metastatic breast cancer;
Oncology News International feb'08

Combined trastuzumab (HER)/docetaxel (TAX) versus sequential trastuzumab followed by docetaxel at progression as first line chemotherapy for Her2-positive metastatic breast cancer: preliminary results (HERTAX).
P Hamberg, JML Stouthard, MM Bos, HJ Braun, F Erdkamp, G van Deijk, M Bontenbal, RM Vernhout, PIM Schmitz, C Seynaeve, JGM Klijn
Breast Cancer Research and Treatment, Vol. 106, Supplement 1, 2007; Abstract 1077

BOOG 2002-04 / HERA
Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J;
Lancet 382:1021-1028, 2013. (IBCSG 28-02) (Journal impact factor 39.060).

Three HERA abstracts were presented at SABCS 2011 (manuscripts under review):
1. Trastuzumab does not increase the incidence of central nervous system (CNS) relapses in HER2 positive early breast cancer: the HERA trial experience
2. Pregnancy during and following adjuvant trastuzumab in patients with HER2-positive breast cancer: An analysis from the HERA trial
3. The magnitude of trastuzumab benefit in HER2-positive (HER2+) lobular breast carcinoma (BC): Results from the HERA Trial
One publication:
Pregnancy during and following adjuvant trastuzumab in patients with HER2-positive breast cancer: An analysis from the HERA trial (BIG 1-01), *Breast Cancer Res Treat*

Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
Younis T, Skedgel C.
Pharmacoeconomics. 2011 May 1;29(5):361-5. doi: 10.2165/11588350-000000000-00000. No abstract available.

HERA crosses over.
Joensuu H.
Lancet Oncol. 2011 Mar;12(3):203-4. Epub 2011 Feb 25. No abstract available.

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team.
Lancet Oncol. 2011 Mar;12(3):236-44. Epub 2011 Feb 25.

The Effect of Age on Breast Cancer Outcomes in Women with Her-2 Positive Breast Cancer: Results from the HERA Trial
Partridge AH, Gelber S, Piccart M, Focant F, Scullion M, Winer E, Gelber R, on Behalf of the HERA Trial Study Team.
Cancer Res; 70(24 Suppl) Dec 15, 2010; P4-09-12

Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience
Zabaglo L, Stoss O, Rueschoff J, Zielinski D, Salter J, Bradbury I, Arfi M, Dafni O, Procter M, Dowsett M, HERA Trial Study Team
Cancer Res; 70(24 Suppl) Dec 15, 2010; PG10-01

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.
J Clin Oncol. 2010 Jul 20;28(21):3422-8. Epub 2010 Jun 7.

The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C, Rayson D, Younis T.
Value Health. 2009 Jul-Aug;12(5):641-8.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B.
J Clin Oncol. 2009 Jun 20;27(18):2962-9. Epub 2009 Apr 13.

When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.
De Rossi C, Brunello A, Jirillo G, Jirillo A.
Immunopharmacol Immunotoxicol. 2009 Mar;31(1):30-1. Review.

When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.
De Rossi C, Brunello A, Jirillo G, Jirillo A.
Immunopharmacol Immunotoxicol. 2009;31(1):1-4.

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.
Ann Oncol. 2008 ;18:909-916.

Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D.
Ann Oncol. 2007 Sep;18(9):1493-9.

The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K.
Breast Cancer Res Treat. 2008 Jun;109(3):559-66. Epub 2007 Jul 28.

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ.
J Clin Oncol. 2007 Sep 1;25(25):3859-65. Epub 2007 Jul 23.

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D Gelber, Sébastien Guillaume, Andrea Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, Jose Baselga, Manfred Kaufmann, David Cameron, Richard Bell, Jonas Bergh, Robert Coleman, Andrew Wardley, Nadia Harbeck, Roberto I Lopez, Peter Mallmann, Karen Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez Rovira, Martine J Piccart-Gebhart, for the HERA study team
The Lancet, Vol 369 (9555):29-36, January 6, 2007

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.
NEJM 2005; 353:1659- 1672.

BOOG 2003-02 / CALOR
Chemotherapy (CT) for Isolated Locoregional Recurrence (ILRR) of Breast Cancer in ER-Positive (ER+) and ER-Negative (ER-) Cohorts: Final Analysis of the CALOR Trial
International Breast Cancer Study Group, Breast International Group, NRG Oncology (NSABP Legacy)
Irene Wapnir, Karen N. Price, Stewart J. Anderson, Andre Robidoux, Miguel Martín, J. W. R. Nortier, Alexander H. G. Paterson, Mothaffar F. Rimawi,
István Láng, José Manuel Baena Cañada, Beat J. K. Thürlimann, Eleftherios P. Mamounas, Charles E. Geyer Jr., Shari Gelber, Alan S. Coates,
Richard D. Gelber, Priya Rastogi, Meredith M. Regan, Norman Wolmark, Stefan Aebi
Poster ASCO 2017

Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial
Irene L. Wapnir, MD1, Shari Gelber, MS2, Stewart J. Anderson, PhD3, Eleftherios P. Mamounas, MD4, Andre´ Robidoux, MD5, Miguel Martı´n, MD6, Johan W. R. Nortier, MD7, Charles E. Geyer Jr, MD8, Alexander H. G. Paterson, MD9, Istva´n La´ng, MD10, Karen N. Price, BS2, Alan S. Coates, MD11, Richard D. Gelber, PhD12, Priya Rastogi, MD13, Meredith M. Regan, ScD14, Norman Wolmark, MD15, Stefan Aebi, MD16, and On behalf of CALOR trial investigators.
Annuals of Surgical Oncology – 2017

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Dr Stefan Aebi, Shari Gelber , Stewart J Anderson, István Láng , André Robidoux , Miguel Martín , Johan W R Nortier , Alexander H G Paterson ,, Mothaffar F Rimawi ,, José Manuel Baena Cañada ,, Beat Thürlimann MD c o, Elizabeth Murray MD p, Eleftherios P Mamounas MD q, Charles E Geyer MD r, Karen N Price ,, Alan S Coates , t, Richard D Gelber ,, Priya Rastogi ,, Norman Wolmark ,, Irene L Wapnir
The Lancet Oncology, Volume 15, Issue 2, Pages 156 - 163, February 2014

Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial (Chemotherapy as Adjuvant for Locally Recurrent Breast Cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)
Aebi S, Gelber S, Láng I, Anderson SJ, Robidoux A, Martín M, Nortier JWR, Mamounas EP, Geyer, Jr. CE, Maibach R, Gelber RD, Wolmark N, Wapnir IL. International Breast Cancer Study Group, Bern, Switzerland; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Breast International Group, Brussels, Belgium
SABCS 2012

Patterns of locoregional failure in the CALOR (Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer) Trial IBCSG 27−02, NSABP B−37, BIG 1−02
Irene L. Wapnir, Shari Gelber, István Láng, Stewart J. Anderson, André Robidoux, Miguel Martín, Johan W.R. Nortier, Eleftherios P. Mamounas, Charles E. Geyer, Jr., Rudolf Maibach, Richard D. Gelber, Norman Wolmark, Stefan Aebi
Accepted SABCS 2012

Progress on BIG 1-02/IBCSG 27-02/ NSABP B-37, A Prospective Randomized Trial of Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer
Irene L. Wapnir, Stefan Aebi, Shari Gelber, Charles E. Geyer, Stewart Anderson, István Láng, Andre Robidoux A, Mamounas EP, Wolmark N
Ann Surg Oncol 15:3227-3231, 2008

A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N.
Clinical Breast Cancer 8:287-292, 2008.

BOOG 2003-04 / BCP
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S.
J Clin Oncol. 2013; 10;31:2532-9

Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S
Cancer Res; 72(24 Suppl) Dec 15, 2012; 514 s (P6-07-05)

Treatment of breast cancer during pregnancy: an observational study.
S. Loibl, S. N. Han, G. Von Minckwitz, M. Bontenbal, A. Ring, J. Giermek, T. Fehm, K. Vanalsteren, S. Linn, B. Schlehe, et al.
The Lancet Oncology. 2012 Sept; 13(9): pag 887-896

Patients with Breast Cancer during Pregnancy – Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03).
Loibl S, Amant F, Kaufmann M, Ring A, Sileny H, Giermek J, Fehm T, Bontenbal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G.
Cancer Res; 70(24 Suppl) Dec 15, 2010; S6-2

Breast cancer in pregnancy: recommendations of an international consensus meeting.
Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A.
Eur J Cancer. 2010 Dec;46(18):3158-68.

Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03)
Loibl S, Bontenbal M, Ring A, UFK FFM NN, Crivellari D, Fehm T, Heinrigs M, Lenhard M, Mehta K, von Minckwitz G
Abstract EBCC 2010

BOOG 2004-01 / Young Boost (CKTO 2003-13)
Factors associated with patient-reported cosmetic outcome in the **Young Boost** Breast Trial.
Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon J, Maduro JH, Russell NS, Scheijmans LJ, Schinagl DA, Westenberg AH, Poortmans P, Boersma LJ; **Young Boost** Trial research group.
Radiother Oncol. 2016 Jul;120(1):107-13. doi: 10.1016/j.radonc.2016.04.017. Epub 2016 May 28.

The influence of the boost dose on cosmetic outcome after breast conserving therapy: results of the Young Boost Trial
P.J.A.M. Brouwers[a], E van Werkhoven[b], B. Hanbeukers[a], J. van Loon[a], J.W. Leer[c], P.M. Poortmans[c], H.Bartelink[b] and L.J. Boersma[a] on behalf of the Young Boost Trial research group.
ESTRO 2015, Barcelona.

Phase III trial of low vs high radiation boost in young breast cancer patients
Boersma L., Bartelink H., Poortmans P.M., Leer J.W.
V&VN-oncologica nummer 01.2011

Multi-institutional study on target volume delineation variation in breast radiotherapy in the presence of guidelines.
van Mourik AM, Elkhuizen PH, Minkema D, Duppen JC; Dutch Young Boost Study Group, van Vliet-Vroegindeweij C**.**
Radiother Oncol. 2010 Mar;94(3):286-91. Epub 2010 Mar 2.

The influence of the use of CT-planning on the irradiated boost volume in breast conserving treatment.
Al Uwini S, Antonini N, Poortmans PM, Boersma L, Hurkmans C, Leer JW, Horiot JC, Struikmans H, Bartelink H.
Radiother Oncol. 2009 Oct;93(1):87-93. Epub 2009 Jun 8.

BOOG 2004-02 / TBP
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; On behalf of the GBG 26/BIG 03-05 study group and participating investigators.
Eur J Cancer. 2011 Jul 7

Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment.
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh F, Baumann K, Bischoff J, Harbeck N, Lück H-J, Maass N, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S.
Cancer Res; 70(24 Suppl) Dec 15, 2010;P6-14-05

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
Gunter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolai Maass, Tanja Cufer, Felix E. de Jongh, Eduard Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer, Klaus H. Baumann, Michael R. Clemens, Ralph Duerr, Christoph Uleer, Michael Andersson, Robert C. Stein, Valentina Nekljudova, and Sibylle Loibl
JCO Vol 27, Nr 12, April 20, 2009

Continuing Trastuzumab Beyond Progression
Jahanzeb M, Division of Hematology Oncology, College of Medicine, University of Tennessee, Memphis, TN, and Aptium Oncology, Lynn Cancer Institute, West Campus, Boca Raton, FL
JCO Vol 27, Nr 12, April 20, 2009

Media Release: Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression (results of a multicenter, randomized phase III study comparing capecitabine alone versus in combination with trastuzumab in patients with HER2-positive metastatic breast cancer and progression after previous treatment with trastuzumab)
German Breast Group, September 14, 2008

Continuering van combinatietherapie bij behandeling van uitgezaaide borstkanker remt ziekteprogressie
Persbericht 9 juni 2008

Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26 / BIG 3-05)
Von Minckwitz G, Zielinski C, Maartense E, du Bois A, Schmidt M, Maass N, Cufer T, De Jongh FE, Andersson M, Stein R, Kaufmann M, Nekljudova V, Loibl S
Presented at the 44th ASCO Annual Meeting 2008, May 30-June 3, Chicago, Illinois , USA

Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer – the TBP study (GBG 26/BIG 3-05).
Von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S
Breast Cancer Research and Treatment, Vol. 106, Supplement 1, 2007; ASCO Abstract 4056

BOOG 2005-02 / MATADOR
Abstract SABCS 2016

GSTP1 polymorphism is associated with chemotherapy-induced neuropathy
N.C.Miltenburg, M.Opdam, M.Winter, M.van Geer, H.M.Oosterkamp, W.Boogerd en S.C.Linn
SABCS 2012

De MATADOR-studie: multicenter fase-III-onderzoek naar chemotherapie op maat bij het mammacarcinoom.
Linn SC, Helgason HH, Oosterkamp HM
Ned Tijdschr Oncol 2005;2:193-8.

BOOG 2005-03 / MINDACT

Checken ofe deze publicaties onderstaand al verwerkt zijn:
Viale G, Slaets L, Bogaerts J, Rutgers E, van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial.
Ann Oncol. 2014 Apr;25(4):816-23. doi: 10.1093/annonc/mdu026.

Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.

Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.
Eur J Cancer. 2009 May;45(7):1201-8. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14.

Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial.
J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.

Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium. The MINDACT trial: the first prospective clinical validation of a genomic tool.
Mol Oncol. 2007 Dec;1(3):246-51. doi: 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22.

Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial.

Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55. Review.

Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. Review.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, ThompsonAM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.
N Engl J Med. 2016 Aug 25;375(8):717-29.

Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) vs clinical subtypes for breast cancer, among 6,694 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial
Giuseppe Viale[1], Leen Slaets[2], Femke A de Snoo[3], Jan Bogaerts[2], Laura J van 't Veer[4], Emiel J Rutgers[5], Martine J Piccart-Gebhart[6], Jeroen van den Akker[3], Lisette Stork-Sloots[3], Leila Russo[1], Patrizia Dell'Orto[1], Fatima Cardoso[7]
SABCS 2014 publication number: P4-11-08

Are all small tumors low risk? Characterization of small invasive node negative breast cancers (BC) enrolled in the EORTC 10041/BIG 3-04 (MINDACT) trial
Konstantinos Tryfonidis[1], Leen Slaets[2], Giuseppe Viale[3], Femke Snoo[4], Laura Van't Veer[5], Emiel Rutgers[6], Martine Piccart[7], Jan Bogaerts[2] and Fatima Cardoso[8].
SABCS 2014, publication number: P2-03-01

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.
Rutgers E1, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso **F.**
Eur J Cancer. 2011 Dec;47(18):2742-9.

The EORTC 10041/BIG 03-04 MINDACT (Microarray in Node Negative Disease may Avoid ChemoTherapy) Trial: Patients' baseline Characteristics and Logistics Aspects After a Successfull Accrual
Piccart M, Bogaerts J, Cardoso F, Werutsky G, Delaloge S, Van 't Veer L, Rubio I, Moulin C, Engelen K, Viale G, Thompson AM, Passalacqua, Nitz U, Vuylsteke P, Pierga JY, Rutgers E
Abstract ESMO 2011

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, Van't Veer LJ; TRANSBIG Consortium.
Breast Cancer Res Treat. 2009 Jul;116(2):295-302.

Clinical application of the 70-gene profile: the MINDACT trial.
Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ.

J Clin Oncol. 2008 Feb 10;26(5):729-35

MINDACT Microarray in Node Negative Disease may Avoid ChemoTherapy. Een unieke studie voor borstkankerpatiënten en onderzoeker.
I. Eekhout, S. Mook, E.Th Rutgers
Nederlands Tijdschrift voor Oncologie, 2008

The MINDACT trial: the first prospective clinical validation of a genomic tool
Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium.
Mol Oncol. 2007 Dec;1(3):246-51.

Individualization of Therapy Using Mammaprint: from Development to the MINDACT trial
Stella Mook, Laura Van't Veer, Emiel Rutgers, Martine Piccart-Gebhart and Fatima Cardoso
CANCER GENOMICS & PROTEOMICS 4: 147-156 (2007)

MINDACT Trial: A prospective trial to validate the Amsterdam signature
Rutgers E.
Breast International Group 1 ASCO 43rd Annual meeting 2007 - Educational Book: 40-44,2007.

Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.
Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55.

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium.
Nat Clin Pract Oncol. 2006 Oct;3(10):540-51.

BOOG 2006-01 / DATA
Abstract ingediend voor SABCS 2011 & geaccepteerd voor poster discussie sessie

Abstract SABCS 2016 oral presentation

BOOG 2006-02 / OMEGA
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
C. H. Smorenburg; S. M. de Groot; A. E. van Leeuwen-Stok; M. E. Hamaker; A. N. Wymenga; H. de Graaf; F. E. de Jongh; J. J. Braun; M. Los; E. Maartense; H. van Tinteren; J. W. R. Nortier; C. Seynaeve
Annals of Oncology 2014; doi: 10.1093/annonc/mdt588

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
M.E. Hamaker, C. Seynaeve, A.N.M. Wymenga, H. van Tinteren, J.W.R. Nortier, E. Maartense, H. de Graaf, F.E. de Jongh, J.J. Braun, M. Los, J.G. Schrama, A.E. van Leeuwen-Stok, S.M. de Groot, C.H. Smorenburg.
Breast 2013;xx: 1-7

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study
M.E. Hamaker, C. Seynaeve, J.W.R. Nortier, M. Wymenga, E. Maartense, E. Boven, A.E. van Leeuwen-Stok, S.E. de Rooij, B.C. van Munster, C.H. Smorenburg
Breast 2013;22:556-9.

First-line chemotherapy with pegylated liposomal doxorubicin (PEGdoxo) versus capecitabine (Cape) in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)
C.H. Smorenburg, C. Seynaeve, A.N.M. Wymenga, E. Maartense, H. de Graaf, F.E. de Jongh, J.J. Braun, M. Los, J.G. Schrama, J.E.A. Portielje, M. Hamaker, H. van Tinteren, S.M. de Groot, A.E. van Leeuwen-Stok, J.W.R. Nortier
Poster SABCS 2012

Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review
Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC.
Lancet Oncol 2012;Vol 13:Issue 11, e437-44.

Resultaten van de klinische studie gepresenteerd op een congres/symposium:
Baseline comprehensive geriatric assessment predicts for toxicity of single agent chemotherapy in elderly metastatic breast cancer patients: results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
M.E. Hamaker, C. Seynaeve, A.N.M. Wymenga, H. van Tinteren, J.W.R. Nortier, E. Maartense, S.M. de Groot, C.H. Smorenburg
ASCO 2012 accepted as poster presentation

Toxicities and feasibility associated with PEG doxo versus Capecitabine (Cape) as first line chemotherapy in elderly metastatic breast cancer patients (OMEGA trial)
C. Seynaeve, H. van Tinteren, ANM Wymenga, JWR Nortier, E. Maartense, FE de Jongh, H. de Graaf, SM de Groot, JJ Braun, CH Smorenburg
EBCC-8 2012 accepted as poster presentation

Reasons for low accrual of elderly patients with metastatic breast cancer in the OMEGA study of the Dutch Breast cancer Trialists' Group (BOOG).
ME Hamaker, C Seynaeve, ANM Wymenga, JWR Nortier, E Maartense, FE de Jongh, H de Graaf, JJ Braun, SM de Groot, AE van Leeuwen-Stok, CH Smorenburg
SIOG November 2011 accepted as oral presentation

De OMEGA studie. Een gerandomiseerde fase III-studie betreffende eerstelijnschemotherapie met gepegyleerd liposomaal doxorubicine of capecitabine bij patienten vanaf 65 jaar met gemetastaseerd mammacarcinoom, inclusief geriatrische evaluatie.
CH Smorenburg, ANM Wymenga, E Maartense, JWR Nortier, C Seynaeve.
Ned Tijdschrift Oncol 2009;6:275-8

Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
Hamberg P, Verweij J, Seynaeve C.
Eur J Cancer. 2007 Jul;43(10):1514-28.

<u>BOOG 2006-03 / SUPREMO</u>

The SUPREMO Trial – Pathology quality assurance of a large phase III randomised international clinical trial.
Jeremy Thomas, Andrew Hanby, Nicola Russell, Geertjan van Tienhoven, Kathleen Riddle, David Cameron, John Bartlett, Tammy Piper, Carrie Cunningham, Peter Canney, Ian Kunkler.
EBCC-10 2016 poster presentation.

Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria. Russell NS, Kunkler IH, van Tienhoven G. *Ann Oncol. 2015 Jun;26(6):1043-4.*

Post-mastectomy radiotherapy- will SUPREMO end the debate? Russell NS, Kunkler I, van Tienhoven

G, Canney PA, Thomas J, Bartlett, J van de Vijver MJ, Belkacemi Y, Yarnold JR, Barrett-lee PJ. J.
Clin Oncol 2009; 27 (6): 996-7.

SUPREMO trial management group. Elucidating the role of chest wall irradiation in "intermediate-risk" breast cancer: the MRC/EORTC SUPREMO trial.
I.H. Kunkler, P. Canney, G. Van Tienhoven, N.S. Russell on behalf of the MRC/EORTC (BIG 2-04)
Clin Oncol 20: 31-34, 2008.

BOOG 2006-04 / TEAM-II
TEAM IIA

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Fontein DB, Charehbili A, Nortier JW, Putter H, Meershoek-Klein Kranenbarg E, Kroep JR, Linn SC, van de Velde CJH.
Eur J Surg Oncol. 2017 Apr;43(4):619-624.

ER pathway activity as a predictive biomarker for neoadjuvant endocrine therapy. Blok et al.
SABCS 2016 P3-07-65.
Radiological evaluation of neo-adjuvant endocrine therapy in hormone-receptor positive early breast cancer. Blok et al.
SABCS 2016 P6-01-05.

BOOG 2006-04TEAM IIB
Abstract SABCS 2016 poster discussion

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.
Lancet. 2015 Oct 3;386(10001):1353-61.

Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - a phase II trial
D.B.Y.Fontein, C.J.H.van de Velde, A.Charehbili, W.M.Meershoek-Klein Kranenbarg, J.W.R.Nortier, J.R.Kroep, H.Putter, G.J.Liefers, S.C.Linn, Y. van Riet, G. Nieuwenhuijzen, B. de Valk, J.M. Meerumterwogt, G. Algie
Eur J Cancer 2014

BOOG 2006-05 / IDEAL
EDITORIAL
Searching for the IDEAL Duration of Adjuvant Endocrine Therapy
Rachel L. Yung, Nancy E. Davidson
JNCI J Natl Cancer Inst (2018)

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok, Judith R. Kroep, Elma Meershoek-Klein Kranenbarg,Marjolijn Duijm-de Carpentier, Hein Putter, Joan van den Bosch,Eduard Maartense, A. Elise van Leeuwen-Stok, Gerrit-Jan Liefers, Johan W.R. Nortier, Emiel J.Th. Rutgers, Cornelis J.H. van de Velde; on behalf of the IDEAL Study Group
JNCI J Natl Cancer Inst (2018)

Optimal duration of extended adjuvant endocrine therapy for early breast cancer.
Blok E, Kroep J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok E, Liefers G, Nortier J, Rutgers E, van de Velde CJH, on behalf of the IDEAL Study Group

J Natl Cancer Inst. 2017, Mid July on-line

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
van de Velde CJH, Blok E, Meershoek-Klein Kranenbarg E, Putter H, van den Bosch J, Maartense E, Duijm-de Carpentier M, van Leeuwen-Stok E, Liefers G, Nortier J, Rutgers E, Kroep J
ECCO abstract January 2017

Abstracts SABCS 2016 oral presentation and poster

High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Fontein DBY, Nortier JWR, Liefers GJ, Putter H, Meershoek-Klein Kranenbarg E, van den Bosch J, Maartense E, Rutgers EJTh, van de Velde CJH, Eur J
(2012) Surg Oncol. 2012 Feb;38(2):110-7. Epub 2011 Dec 14.

High Rates of Nonadherence to Aromatase Inhibitors in the Extended Adjuvant Setting
DBY Fontein, JWR Nortier, H Putter, E Meershoek-Klein Kranenbarg, EJTh Rutgers, CJH van de Velde
Poster #: 5.162 op ECCO 16, 24-27 September 2011, Stockholm

Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients.
Kool M, Fontein DB, Meershoek-Klein Kranenbarg E, Nortier JW, Rutgers EJ, Marang-van de Mheen PJ, van de Velde CJH.
Breast. 2015 Jun;24(3):224-9.

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJH, Kroep JR.
Cancer Treat Rev. 2015 Mar;41(3):271-6.

BOOG 2006-06 / ATX
Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E.
Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.326.

The role of pharmacogenetics in capecitabine efficacy and toxicity.
Lam SW, Guchelaar HJ, Boven E.
Cancer Treat Rev. 2016 Aug 10;50:9-22. doi: 10.1016/j.ctrv.2016.08.001. Review.

Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.
Lam SW, Nota NM, Jager A, Bos MM, van den Bosch J, van der Velden AM, Portielje JE, Honkoop AH, van Tinteren H, Boven E; ATX Trial Team..
Clin Cancer Res. 2016 Apr 1;22(7):1611-20. doi: 10.1158/1078-0432.CCR-15-1005.

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN, Lam SW, Guchelaar HJ, Boven E.
Cancer Treat Rev. 2015 Dec;41(10):935-50. doi: 10.1016/j.ctrv.2015.10.010. Review.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.
Eur J Cancer. 2014 Dec;50(18):3077-88.

Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
Siu W Lam[1], Nienke M Nota[1], Steffen M de Groot[2], Agnes Jager[3], Monique MEM Bos[4], Sabine C Linn[5], Joan van den Bosch[6], Hans J Braun[7], Ankie MT van der Velden[8], Maartje Los[9], Johanneke EA Portielje[10], Judith R Kroep[11], Aafke H Honkoop[12], Carolien H Smorenburg[13], Bea Tanis[14], Johanna MGH van Riel[15], Jetske M Meerum Terwogt[16], Marien O den Boer[17], Joep Douma[18], Frank Jeurissen[19], Johan Berends[20], Harm van Tinteren[5] and Epie Boven[1].
SABCS 2014, publication number P3-06-09

Genetic polymorphisms (SNPs) as predictive markers for paclitaxel-induced peripheral neuropathy (PNP) and capecitabine-induced hand-foot syndrome (HFS) in HER-2 negative metastatic breast cancer patients
Siu W Lam[1], Charlotte N Frederiks[1], Tahar van der Straaten[2], Steffen M de Groot[3], Agnes Jager[4], Monique MEM Bos[5], Sabine C Linn[6], Joan van den Bosch[7], Hans J Braun[8], Ankie MT van der Velden[9], Maartje Los[10], Jojanneke EA Portielje[11], Judith R Kroep[2], Aafke H Honkoop[12], Carolien H Smorenburg[13], Bea Tanis[14], Johanna MGH van Riel[15], Jetske M Meerum Terwogt[16], Marien O den Boer[17], Joep Douma[18], Frank Jeurissen[19], Johan Berends[20], Henk-Jan Guchelaar[2] and Epie Boven[1].
SABCS 2014 publication number P6-08-09

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial
S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven, on behalf of the Dutch Breast Cancer Research Group (BOOG).
Eur J Cancer 2014 (conditionally accepted)

Plasma VEGF-A, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
S.W. Lam, S.M. de Groot, A.H. Honkoop, N.M. Nota, A. Jager, A.W.T van der Velden, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, R.R. de Haas, C.H. Smorenburg, H. de Graaf, J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren and E. Boven.
J Clin Oncol 31, 2013 (suppl; abstr 1072)

Plasma VEGF-A, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
S.W. Lam, S.M. de Groot, A.H. Honkoop, N.M. Nota, A. Jager, A.W.T van der Velden, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, R.R. de Haas, C.H. Smorenburg, H. de Graaf J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren and E. Boven.
Abstract ASCO 2013

Combination of paclitaxel and bevacizumab without or with capecitabine as first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): first results from a randomized, multicenter, open-label, phase II study of the Dutch Breast Cancer Trialists' Group (BOOG) (abstract)
S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.W.R. Nortier, J.J. Braun, H. de Graaf, J.E.A. Portielje, M. Los, D.D. Gooyer, H. van Tinteren, E. Boven, *SABCS 2011*

BOOG onderzoekt combinatie bevacizumab met chemotherapie bij mammacarcinoom
E. Boven, A.H. Honkoop, H. van Tinteren C.L. van der Wilt, A.E. van Leeuwen-Stok
NvMO tijdschrift, 2008

ATX-studie: een multicentrische gerandomiseerde fase II BOOG-studie naar de behandeling van HER2-negatief gemetastaseerd mammacarcinoom.

E. Boven, A.H. Honkoop, C.L. van der Wilt, A.E. van Leeuwen-Stok
Ned. Tijdschrift voor Oncologie, 2007, Vol.4, nr. 8, p. 376-378.

BOOG 2006-07 / MIRROR

Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.
M.J. Pepels, M. de Boer, P. Bult, J.A.A.M. van Dijck, C.H.M. van Deurzen, M.B.E. Menke-Pluymers, P.J. van Diest, G.F. Borm, and V.C.G. Tjan-Heijnen
Ann Surg, in press

Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location.
J.H.M.J. Vestjens, M. de Boer, P.J. van Diest, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, E.M.M. Adang, P. Bult, and V.C.G. Tjan-Heijnen.
Breast Cancer Res Treat, in press

Relevant impact of central pathology review on nodal classification, but not on the association of small nodal metastases with breast cancer outcome. Results from the Dutch MIRROR study.
J.H.M.J. Vestjens,, M. de Boer, G.F. Borm, C.H.M. van Deurzen, P.J. van Diest, J.A.A.M. van Dijck, E.M.M. Adang, J.W.R. Nortier, E.J.T.Rutgers C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, and V.C.G. Tjan-Heijnen
Abstract PD06-04, poster presentation. San Antonio Breast Cancer Conference 2010, San Antonio, Texas, USA.
Cancer Res; 70(24 Suppl) Dec 15, 2010; PD06-04.

Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes.
M. de Boer, E.M.M. Adang, K. C. Van Dycke, J A.A.M. van Dijck, G.F. Borm, C.H.M. van Deurzen, P.J. van Diest, P. Bult, A.R.T. Donders, V.C.G. Tjan-Heijnen.
Abstract #614, poster presentation. ASCO Annual Meeting 2010, Chicago, Illinois, USA.
J Clin Oncol 28:15s, 2010.

Micrometastases and isolated tumor cells in breast cancer are indeed associated with poorer outcome.
P.J. van Diest, M. de Boer, C.H.M. van Deurzen, V.C.G. Tjan-Heijnen.
J Clin Oncol 2010; 28(9):e140; author reply e141-2.

Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study.
M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C.Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen
Abstract #CRA506, oral presentation, ASCO Annual Meeting 2009, Orlando, Florida, USA.
J Clin Oncol 27:18s, 2009.

Isolated tumor cells in axillary lymph nodes of breast cancer patients: differential prognostic impact of single tumor cell(s) versus tumor cell clusters, and microanatomic location. New results from the Dutch MIRROR study.
P.J. van Diest, H. Schut, M. de Boer, C.H.M. van Deurzen, J.A.AM. van Dijck, G.F. Borm, E.M.M. Adang, P. Bult, and V.C.G. Tjan-Heijnen.
Abstract #306, poster discussion session. San Antonio Breast Cancer Conference 2009, San Antonio, Texas, USA.

Isolated Tumor Cells in Breast Cancer
Correspondence to the editor, N Engl J Med 361:1994-1996, November 12, 2009

Minimal lymph node involvement and outcome of breast cancer. The results of the Dutch MIRROR study.Tjan-Heijnen VC, de Boer M.
Discov Med. 2009 Oct;8(42):137-9.

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer
M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen.
N Engl J Med 361:653-63, August 13, 2009

Micrometastases and isolated tumor cells: relevant and robust or rubbish? (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists' group (BOOG).
M. de Boer, C.H.M. van Deurzen, J.A.A.M. van Dijck, G.F. Borm, P.J. van Diest, E.M.M. Adang, J.W.R. Nortier, E.J.Th. Rutgers, C. Seynaeve, M.B.E. Menke-Pluymers, P. Bult, V.C.G. Tjan-Heijnen.
Abstract #23, oral presentation. San Antonio Breast Cancer Conference 2008, San Antonio, Texas, USA.

BOOG 2007-01 / ALLTO
Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial
Minetta C Liu[1], Brigitte Rack[2], Amylou C Dueck[4], David W Hillman[1], Michael B Campion[1], Monica M Reinholz[3], Kevin C Halling[1], Christos Sotiriou[5], Françoise Rothé[5], Marion Maetens[5], Ghizlane Rouas[5], Wolfgang Janni[6], Antonio C Wolff[7], Lyndsay N Harris[8], Julie R Gralow[9], Kathleen I Pritchard[10], Susan Ellard[12], Nguyet A Le-Lindqwister[13], Frances Boyle[14], Evandro De Azambuja[5], Martine J Piccart-Gebhart[5], Michail Ignatiadis[5] and Edith A Perez[11].
SABCS 2014, publication number: P4-01-01

Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial
McCullough AE, Dell'Orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Lingle WL, Jackisch C, Perez EA, Piccart-Gebhart MJ, Viale G.
Cancer Res; 70(24 Suppl) Dec 15, 2010; P3-10-06

Adjuvant Lapatininb en/of Trastuzumab Treatment Optimalization studie (ALTTO, BOOG 2007-01)
J.W.R.Nortier, *NTvO juni 2009*

The new generation of breast cancer clinical trials: the right drug for the right target].
De Azambuja E, Cardoso F, Meirsman L, Straehle C, Dolci S, Vantongelen K, Piccart-Gebhart M.
Bull Cancer. 2008 Mar;95(3):352-7. Review. French.

Jumping higher: is it still possible? The ALTTO trial challenge
G. Tomassello, E. de Azambuja, P. Dinh,N. Snoj and M. Piccart-Gebhart; *Expert Rev. Anticancer Ther. 8(12), 1883-1890 (2008)*

BOOG 2007-02 / INTENS
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists'.
Eur J Cancer 2013 Oct;49(15):3102-10

Neoadjuvant chemotherapy and pathologic complete response in relation to clinical response, results from a phase III study (INTENS) of the Dutch breast cancer trialists' group (BOOG).
VCG Tjan-HeijnenA, BEPJ VriensA, B de VriesA, SM van GastelB, J WalsC, TJ SmildeD, LJC van WarmerdamE, HWM van LaarhovenF , DJ van SpronsenG, GF BormF
SABCS 2012

Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), toxicity results from a phase III study of the Dutch breast cancer trialists' group (BOOG).
Vriens BEPJ, Van de Vijver KKBT, Boetes C, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJC, van Laarhoven HWM, van Spronsen DJ, Borm GF, Tjan-Heijnen VCG.
Cancer Res; 71 (24 Suppl) Dec 15, 2011

Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch breast cancer trialists' group (BOOG).
Vriens BE, Van de Vijver KK, Boetes C, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, van Laarhoven HW, van Spronsen DJ, Borm GF, Tjan-Heijnen VCG.
Cancer Res; 70(24 Suppl) Dec 15, 2010;

BOOG 2008- 01 / 2-2-6 G-CSF

Primary Granulocyte Colony-Stimulating Factor for Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in patients with breast cancer at risk for febrile neutropenia
M.J. Aarts, F.P. Peters, C.M. Mandigers, M.W. Dercksen, J.M. Stouthard, J.W.R. Nortier, H.W. van Laarhoven, L.J. van Warmerdam, A.J. van de Wouw, E.M. Jacobs, V. Mattijssen, C.C. van der Rijt, T.J. Smilde, A.W. van der Velden, M. Temizkan, E. Batman, E.W. Muller, S.M. van Gastel, G.F. Borm, V.C. Tjan-Heijnen,.
J Clin Oncol 2013; April 29, [Epub ahead of print]

Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC.
J Clin Oncol. 2013 Dec 1;31(34):4283-9. doi: 10.1200/JCO.2012.48.3644. Epub 2013 Oct 28.

Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC.
J Clin Oncol. 2013 Dec 1;31(34):4290-6. doi: 10.1200/JCO.2012.44.6229. Epub 2013 Apr 29

Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia.
Aarts MJ, Peters FP, Mandigers CM, Dercksen WM, Stouthard JM, Nortier JWR, van Laarhoven HWM, van Warmerdam LJ, van de Wouw YA, Jacobs EM, Mattijssen VE, van der Rijt CCD, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van der Vegt SG, van Gastel SM, Borm GF, Tjan-Heijnen VCG, *(2012) (submitted)*

Primary G-CSF prophylaxis during the First Two cycles only or Throughout All chemotherapy cycles in breast cancer patients at risk of Febrile Neutropenia: First results from a phase III trial of the Dutch Breast Cancer Trialists Group (BOOG)
M.J.B. Aarts, F.P.J. Peters, M.W. Dercksen, C. Mandigers, S. van Gastel, V.C.G. Tjan-Heijnen
Support Care Cancer 2010;18 (Suppl 3):S 09-078

Primary G-CSF prophylaxis during the First Two cycles only or Throughout All chemotherapy cycles in breast cancer patients at risk of Febrile Neutropenia: Final results from a phase III trial of the Dutch Breast Cancer Trialists Group (BOOG)
M.J.B. Aarts, F.P.J. Peters, M.W. Dercksen, C.Mandigers, J.Stouthard, J.W.R. Nortier, Y.J.L. Kamm, L.J.C. van Warmerdam, C.D. van der Rijt, S. van Gastel, M. Joore, A. Kessels, V.C.G. Tjan-Heijnen

Cancer Res; 2010;70(24) Suppl2; P3-15-01

BOOG 2008-02 / A6181099 (SUTENT)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M.
Breast Cancer Res Treat. 2010 May;121(1):121-31. Epub 2010 Mar 26.

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).
J. Crown, V. Dieras, E. Staroslawska, D. A. Yardley, N. Davidson, T. D. Bachelot, V. R. Tassell, X. Huang, K. A.Kern, G. Romieu;
J Clin Oncol 28:18s, 2010 (suppl; abstr LBA1011)

BOOG 2008-03 / HAT

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S.
Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17.

Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA-HAT) at progression as first-line treatment for patients with Her2 positive metastatic breast cancer: The HAT-Study
Jan C Drooger[1], Harm van Tinteren[2], Steffen M de Groot[3], Albert J ten Tije[4], Hiltje de Graaf[5], Johanneke EA Portielje[6], Agnes Jager[1], Aafke H Honkoop[7], Sabine C Linn[2], Judith R Kroep[8], Frans LG Erdkamp[9], Paul Hamberg[10], Joan B Heijns[4], A Elise van Leeuwen-Stok[11] and Stefan Sleijfer[1].
SABCS 2014, publication number: P4-15-12

BOOG 2008-03/HAT-studie: Een gerandomiseerde fase II-studie bij patiënten met gemetastaseerde borstkanker met Her2/neu-overexpressie
J.Ph. van den Tol en S. Sleijfer;
NTvO, 2009, Vol.6 nr 8:365-66

BOOG 2009-01 / IRMA

Nog geen publicaties

BOOG 2009-02 / SNARB

Sentinel Node and Recurrent Breast Cancer (SNARB): Results of a Nationwide Registration Study
Maaskant AJG, Roumen RMH, Voogd AC, Pijpers R, Luiten EJT, Rutgers EJT, Nieuwenhuijzen GAP
Annals of Surgical Oncology (2012), DOI 10.1245/s10434-012-2625-7

Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure
F.Derkx, A.J.G. Maaskant-Braat, M.J.C. van der Sangen, G.A.P. Nieuwenhuijzen, L.V. van de Poll-Franse, R.M.H. Roumen, A.C. Voogd
Eur J Surg Oncol (2010), doi:10.1016/j.ejso.2010.05.009

Schildwachtklierprocedure bij recidief mammacarcinoom (SNARB); resultaten van een interim-analyse
Maaskant AJG, Bruijn de S, Roumen RMH, Nieuwenhuijzen GAP
Catharina-ziekenhuis, Eindhoven, afdeling Heelkunde

Abstract Chirurgendagen NVH 21-05-2010

Schildwachtklierprocedure: ook een mogelijkheid bij patiënten met een recidief van een mammacarcinoom
R.M.H. Roumen, G.P. Kuijt en I.H. Liem
Ned Tijdschr Geneeskd. 2008;152:13-9

BOOG 2009-03 / DCIS
Patient-reported outcomes in ductal carcinoma in situ (DCIS): A systematic review. *European Journal of Cancer*, Accepted 7th October 2016. King MT, Winters Z, Butow P, Chua B, Saunders C, Spillane A, Mann GB, Olivotto I, Westenberg AH, Burnett P, Rutherford C.

BOOG 2009-04 / Male Breast cancer
Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Fatima Cardoso, John M.S. Bartlett, Leen Slaets, Carolien H.M. van Deurzen, Elise van Leeuwen-Stok, Peggy Porter, Barbro Linderholm, Ingrid Hedenfalk, Carolien Schröder, John Martens, Jane Bayani, Christi van Asperen, Melissa Murray, Clifford Hudis, Lavinia Middleton, Joanna Vermeij, Kevin Punie, Judith Fraser, Monika Nowaczyk, Isabel T. Rubio, Stefan Aebi2 Catherine Kelly, Kathryn J. Ruddy, Eric Winer, Cecilia Nilsson, Lissandra Dal Lago, Larissa Korde, Kim Benstead, Oliver Bogler, Theodora Goulioti, Aleksandra Peric, Saskia Litière, Kim C. Aalders, Coralie Poncet, Konstantinos Tryfonidis, and Sharon H. Giordano
Annals of Oncology, 2017

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Marijn A. Vermeulen, Leen Slaets, Fatima Cardoso, Sharon H. Giordano, Konstantinos ryfonidis, Paul J. van Diest,Nizet H. Dijkstra, Carolien P. Schröder, Christi J. van Asperen, Barbro Linderholm, Kim Benstead, Renee Foekens, John W.M. Martens, John M.S. Bartlett, Carolien H.M. van Deurzen
European Journal of Cancer (2017) 1-9

Characterization of male breast cancer: First results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program
F. Cardoso, J. Bartlett, L. Slaets, C. van Deurzen, E. van Leeuwen-Stok, P. Porter, B. Linderholm, I. Hedenfalk, C. Schröder, J. Martens, J. Bayani, C. van Asperen, M. Murray, C. Hudis, L. Middleton, J. Vermeij, S. Peeters, J. Fraser, M. Nowaczyk, I.T. Rubio, S. Aebi, C. Kelly, K. Ruddy, E. Winer, C. Nisson, L. Dal Lago, L. Korde, K. Benstead, D. van den Weyngaert, O. Bogler, Th. Goulioti, N. Dif, C. Messina, K. Tryfonidis, J. Bogaerts and S. Giordano
SABCS 2014 - Abstract no. S6-05

Male breast cancer in the Netherlands: uptake and outcome of BRCA testing
Results of study the Dutch Breast Cancer Research Group (BOOG 2009-04) in collaboration with the EORTC 10085 study.
CJ van Asperen, N Dijkstra, PJM van Hees, WAG van Zelst-Stams, JC Oosterwijk, MGE Ausems, RA Oldenburg, MA Adank, EW Blom, M Ruijs, TAM van Os, LAM Janssen, CHM van Deurzen, S Roshani, JWM Martens, CP Schroder
European Society Human Genetics (ESHG 2014, Milaan) – Abstract no. P12.085-S.

Pathologic prognostic factors of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABG International Male Breast Cancer Program
M.A. Vermeulen, L. Slaets, F. Cardoso, S. Giordano, S. Aebi, J. Bayani, P.J. van Diest, J. Fraser, T. Goulioti, C. Kelly, E. van Leeuwen-Stok, B. Linderholm, J. Martens, S. Peeters, P. Porter, I. Rubio, C. Schroder, K. Tryfonidis, J.M.S. Bartlett, C.H.M. van Deurzen
EBCC 2016 – Abstract 7

Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
S.C. Doebar, L. Slaets, F. Cardoso, S.H. Giordano, J.M.S. Bartlett, K.Tryfonidis, N. Dijkstra, C.P. Schröder, C. van Asperen, B.Linderholm, Representative of Cheltenham Gen Hosp, S. Peeters, W.N. Dinjens, R. van Marion, P.J. van Diest, J.W. Martens, CHM. van Deurzen
Accepted for publication in Modern Pathology.

BOOG 2009-05 / BOLERO-2
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.
JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.1279. [Epub ahead of print]

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J.
J Clin Oncol. 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. Epub 2015 Oct 26.

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study.
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M.
Eur J Cancer. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. Epub 2013 Jun 1.

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI.
J Natl Cancer Inst. 2013 May 1;105(9):654-63. doi: 10.1093/jnci/djt026. Epub 2013 Feb 19.

Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S.
Cancer. 2013 May 15;119(10):1908-15. doi: 10.1002/cncr.28010. Epub 2013 Mar 15.

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.
Breast Cancer. 2013 Feb 13. [Epub ahead of print]

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN.
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial
Baselga J, Campone M, Sahmoud T, Piccart M, Burris H, Rudo H, Noguchi S, Gnant M, Mukhopadhyay P, Hortobagyi G
Abstract ESMO 2011
Presentatie ECCO 2011

BOOG 2010-01 / NEO-ZOTAC

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies. Vriens BE, Keymeulen KB, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJ, Heuts EM, Tjan-Heijnen VC, The Dutch Breast Cancer Research Group Boog.
Oncotarget. 2017 Feb 4. [Epub ahead of print]

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
J.R. Kroep, A. Charehbili, R.E. Coleman, R.L. Aft, Y. Hasegawa, M.C. Winter, K. Weilbaecher, K. Akazawa, S. Hinsleyf, H. Putter, G.J. Liefers, J.W.R. Nortier, N. Kohno
European Journal of Cancer 54 (2016) 57-63

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2016 Jan 6;18(1):3

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJ, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Breast. 2016 Feb;25:69-74.

Serum vit D levels and response to molecular subtypes in breast cancer.
Kroep J, Charehbili A, Hamdy N.
Breast. 2016 Jun;27:186.

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJ, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.
Mol Cancer Ther. 2015 Mar;14(3):821-7.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van BA, van Laarhoven HW, Meershoek-Klein KE, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR
Breast Cancer Res Treat 2015;149:461-466.

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
Dekker TJ, Charehbili A, Smit VT, ten Dijke P, Kranenbarg EM, van de Velde CJ, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR.

Mol Oncol. 2015 Jun;9(6):1120-8

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, Janssen LG, Swen JJ, Smit VT, Heijns JB, Kessels LW, van der Straaten T, Böhringer S, Gelderblom H, van der Hoeven JJ, Guchelaar HJ, Pijl H, Kroep JR; Dutch Breast Cancer Research Group.
Breast Cancer Res. 2016 Jan 6;18(1):3.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JW, Kohno N.
Eur J Cancer. 2015 Dec 23;54:57-63.

Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia.
Charehbili A, de Groot S, van der Straaten T, Swen JJ, Pijl H, Gelderblom H, van de Velde CJH, Nortier J, Guchelaar HJ, Kroep JR.
Pharmacogenomics. 2015 Jul;16(11):1-10.

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01). Charehbili A, Hamdy NA, Smit VT, Kessels L, van Bochove A, van Laarhoven HW, Putter H, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van der Hoeven JJ, van de Velde CJH, Nortier JW, Kroep JR; Dutch Breast Cancer Research Group (BOOG).
Breast. 2015 Nov 21 [Epub ahead of print]

Op het SABCS had Stefanie de Groot een poster:
Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01). de Groot S et al. *SABCS 2016, publication number P3-07-54.*

Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)
S de Groot[1], A Charehbili[1], L GM Janssen[1], E M Dijkgraaf[1], V THBM Smit[1], L W Kessels[2], A van Bochove[3], H WM van Laarhoven[4], E Meershoek-Klein Kranenbarg[1], A E van Leeuwen-Stok[5], G J Liefers[1], C JH van de Velde[1], J WR Nortier[1], J JM van der Hoeven[1], H Pijl[1] and J R Kroep[1].
SABCS 2014, publication number: P3-06-50

Sentinel node procedure before or after neoadjuvant chemotherapy in clinically node negative or positive patients; results from 3 phase III studies of the Dutch breast cancer trialists' group (BOOG)
Vivianne C Tjan-Heijnen[1], Birgitte E Vriens[1], Maureen J Aarts[1], Judith R Kroep[2], Cock J van de Velde[2], Gerrit-Jan Liefers[2], Ayoub
Charehbili[2], Petronella G Peer[3] and Maaike de Boer[1].
Abstract SABCS, publication number P2-01-03

Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven HW, Vriens B,

Wasser MN, van Leeuwen-Stok AE, Liefers GJ, van de Velde CJ, Nortier JW, Kroep JR.*Annals of Oncology. 2014 May; 25(5):998-1004*

Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomized trials.
Colemen RE et al.
2013 San Antonio Breast Cancer Symposium. Abstract S4-07.

Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer. Charehbili A et al. *European Cancer Congress 2013- Oral presentation, Abstract No: 1858*

NEO-ZOTAC: Efficacy of NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC*) A Dutch Breast Cancer Trialists' Groups (BOOG) study.*
Charehbili A, van de Ven S, Liefers GJ, Smit VTHBM, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E , van Laarhoven H, Vriens B, Wasser MN, Hamdy NAT, Meershoek-Klein Kranenbarg EM, van Leeuwen-Stok AE, van de Velde CJH, Nortier JWR, Kroep JR.
ASCO Annual Meeting 2013 - Abstract No: 1028.

NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with orwithout ZOledronic acid for patients with HER2-negative large resectable or locally advanced breast cancer
van de Ven S, Charehbili A, Liefers GJ, Putter H, Heijns JB, van Warmerdam LJ, Kessels L, Dercksen M, Pepels MJ, Maartense E, van Laarhoven H, Vriens B, Smit VT, Wasser, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJH, Nortier JWR, Kroep JR
Abstract SABCS 2012 PD07-06

NEO-ZOTAC: A Phase III Randomized Trial with Neoadjuvant Chemotherapy (TAC) with or without Zoledronic Acid for Patients with HER2-Negative Large Resectable or Locally Advanced Breast Cancer.
Abstract SABCS 2011, Program Number: OT1-01-04

Een nieuwe rol voor bisfosfonaten in de behandeling van het mammacarcinoom; het anti-tumoreffect?
Van de Ven S, Kroep JR, Hamdy NAT, Sleeboom AP, Nortier JWR:
Ned Tijdschr Geneeskd. 2010;154:A1951

Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, Kroep JR, Nortier JW, van de Ven S, Heijns JB, Kessels LW, van Laarhoven HW, Bos MM, van de Velde CJH, Gratama JW, Sieuwerts AM, Martens JW, Foekens JA, Sleijfer S.
Mol Cancer Ther. 2015 Mar;14(3):821-7.

Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
Dekker TJ, Charehbili A, Smit VT, Ten Dijke P, Meershoek-Klein Kranenbarg E, van de Velde CJH, Nortier JW, Tollenaar RA, Mesker WE, Kroep JR.
Mol Oncol. 2015 Jun;9(6):1120-8.

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJH, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR.
Breast Cancer Res Treat. 2015 Jan;149(2):461-6.

BOOG 2010-03 / RAPCHEM

Radiotherapy After Primary CHEMotherapy (RAPCHEM): a prospective registration study

L. Boersma, P. Elkhuizen, R. Houben, E. van Leeuwen, S. Linn, L. de Munck, R. Pijnappel, L. Strobbe, T. van Dalen, J. Verloop, A. Voogd, J. Wesseling, P. Poortmans.

Abstract EBCC 2016

BOOG 2010-05 / SUBMIT

SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation

Jetske Ruiterkamp1, Adri C Voogd2, Vivianne CG Tjan-Heijnen3, Koop Bosscha4, Yvette M van der Linden5, Emiel JTh Rutgers6, Epie Boven7, Maurice JC van der Sangen8, Miranda F Ernst39* and In collaboration with Dutch Breast Cancer Trialists' Group (BOOG)

BMC Surgery 2012, 12:5 doi:10.1186/1471-2482-12-5

The role of surgery in metastatic breast cancer

47 Suppl 3:S6-22. doi: 10.1016/S0959-8049(11)70142-3.

Ruiterkamp J, Ernst MF.

Eur J Cancer. 2011 Sep

Presence of symptoms and timing of surgery do not affect the prognosis of patients with primary metastatic breast cancer.

Ruiterkamp J, Voogd AC, Bosscha K, Roukema JA, Nieuwenhuijzen GA, Tjan-Heijnen VC, Ernst MF.

Eur J Surg Oncol. 2011 Oct;37(10):883-9. doi: 10.1016/j.ejso.2011.07.004. Epub 2011 Aug 16.

Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nation wide population-based study in The Netherlands.

Ruiterkamp J, Ernst MF, de Munck L, van der Heiden-van der Loo M, Bastiaannet E, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC.

Breast Cancer Res Treat. 2011 Jul;128(2):495-503. doi: 10.1007/s10549-011-1349-x. Epub 2011 Jan 15.

Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature.

Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VC, Ernst MF.

Breast Cancer Res Treat. 2010 Feb;120(1):9-16. doi: 10.1007/s10549-009-0670-0. Epub 2009 Dec 13. Review.

Jetske Ruiterkamp Thesis 'Surgery in metastatic breast cancer'

BOOG 2012-01 BALLET

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).

Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, Lorizzo K, Bianchetti S, Conte P.

Ann Oncol. 2016 Sep;27(9):1719-25. doi: 10.1093/annonc/mdw249. Epub 2016 Jun 29

Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04)

Guy Jerusalem[1], Gabriella Mariani[2], Eva M Ciruelos[3], Miguel Martin[4], Vivianne CG Tjan-Heijnen[5], Patrick Neven[6], Joaquin Gavila Gregori[7], Andrea Michelotti[8], Filippo Montemurro[9], Istvan Lang[10], Josef Mardiak[11], Bjoem Naume[12], Maura Camozzi[13], Katia Lorizzo[13], Dariusz Brenski[13] and Pierfranco Conte[14]. [1]CHU Sart Tilman Liege and Liege University, Liege, Belgium; [2]Fondazione IRCCS Instituto Nazionale dei Tumori,

Milan, Italy; [3]University Hospital 12 de Octubre, Madrid, Spain; [4]Hospital General Universitario Gregorio Marañón, Madrid, Spain; [5]Maastricht University Medical Centre, Maastricht, Netherlands; [6]KU Leuven and University Hospital Leuven, Leuven, Belgium; [7]Fundacion Instituto Valenciano de Oncologia, Valencia, Spain; [8]Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Pisa, Italy; [9]Fondazione del Piemonte per l'Oncologia, Institute of Candiolo Cancer Center (IRCCs), Candiolo (Torino), Italy; [10]National Institute of Oncology, Budapest, Hungary; [11]National Cancer Institute, Bratislava, Slovakia (Slovak Republic); [12]Oslo University Hospital and Norwa and K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Oslo, Norway; [13]Novartis Farma S.p.A., Origgio/VA, Italy and [14]Istituto Oncologico Veneto IRCCS and Università di Padova, Padova, Italy.
SABCS 2014, publication number: P5-19-02

BOOG 2012-02 / SafeHer

Poster presented at EBCC, March 2016, Amsterdam, The Netherlands
"SafeHer Phase III study primary analysis: Safety of subcutaneous trastuzumab plus chemotherapy for early breast cancer"
EBCC 2016 abstract number: 326

Poster presented at the European Cancer Congress 2015, September 25–29 2015, Vienna, Austria
"Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses"
EBCC 2016 abstract number: 343

"SafeHer Phase III study primary analysis: Safety of subcutaneous trastuzumab plus chemotherapy for early breast cancer"
J. Gligorov[(1)], B. Ataseven[(2)], M. Verrill[(3)], M. De Laurentiis[(4)], K.H. Jung[(5)], H.A. Azim[(6)], N. Al-Sakaff[(7)], S. Lauer[(8)], M. Shing[(9)], X. Pivot[(10)]
EBCC 2016 poster presentation

BOOG 2012-03 / TRAIN-2

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenburg CH, Stouthard JM, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).
Breast. 2016;29:153-9.

Safety analyses of the first 110 patients treated with dual HER2-blockade in the TRAIN-2 study
Mette S van Ramshorst[1*], Erik van Werkhoven[2], Aafke H Honkoop[3], Vincent O Dezentjé[4], Irma M Oving[5], Ingrid AM Mandjes[2], Inge Kemper[1], Jacqueline M Stouthard[1], Sjoerd Rodenhuis[1], Sabine C Linn[1], Gabe S Sonke[1*]
EBCC 2016 abstract number 343

BOOG 2013-04 / DIRECT

The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR.
BMC Cancer. 2015 Oct 5;15:652.

BOOG 2013-06 / BIOMARKER EVEROLIMUS

PI3K-Akt-mTOR pathway analysis to obtain further insight in the efficacy of everolimus in combination with exemestane in metastatic, ER-positive breast cancer: A Dutch breast cancer research group (BOOG) study Dinja T Kruger[1], Karin Beelen[2], Connie R Jimenez[1], Maurice PHM Jansen[3], Stefan Sleijfer[3], Sabine C Linn[2] and Epie Boven[1]..
SABCS 2014, publication mumber: OT1-1-02

De Everolimus Biomarker Studie: analyse van de PI3K-Akt-mTOR route om meer inzicht te verkrijgen in de effectiviteit van everolimus in combinatie met exemestaan bij gemetastaseerd mammacarcinoom - Een studie van de Borstkanker Onderzoek Groep (BOOG) Nederland
Kruger DT, Linn SC, Beelen K, Sleijfer S, Jansen MPHM, Jimenez CR, Boven E.
Ned Tijdschr Oncol 2014;11:250-254

Biomarker Study Everolimus, een studie van de Borstkanker Onderzoek Groep Nederland
Kruger DT, Beelen K, Sleijfer S, Jansen MPHM, Jimenez CR, Linn SC, Boven E.
Kanker Breed 2014;6:23-25

BOOG 2014-01 / MONALEESA-2
Poster presented at SABCS, December 2016, San Antonio.
First-line Ribociclib + Letrozole in Patients With De Novo HR+, HER2– Advanced Breast Cancer: A Subgroup Analysis of the MONALEESA-2 Trial. Publication number P4-22-05.
Joyce O'Shaughnessy, Katarina Petrakova,Gabe S. Sonke, Fabrice André, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Deborah Lindquist, Farida Souami, Xiaodong Li, Caroline Germa, Samit Hirawat, Gabriel N. Hortobagyi.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
"The new England journal of medicine". This article was published on October 8, 2016, at NEJM.org
G.N. Hortobagyi, S.M. Stemmer, H.A. Burris, Y.-S. Yap, G.S. Sonke, S. Paluch‑Shimon, M. Campone, K.L. Blackwell, F. Andre, E.P. Winer, W. Janni,S. Verma, P. Conte, C.L. Arteaga, D.A. Cameron, K. Petrakova, L.L. Hart,C. Villanueva, A. Chan, E. Jakobsen, A. Nusch, O. Burdaeva, E.-M. Grischke, E. Alba, E. Wist, N. Marschner, A.M. Favret, D. Yardley, T. Bachelot, L.-M. Tseng,S. Blau, F. Xuan, F. Souami, M. Miller, C. Germa, S. Hirawat, and J. O'Shaughnessy.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.
N Engl J Med. 2016 Oct 7.

BOOG 2014-03 / OLYMPIA
OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline *BRCA1/2* mutation (gBRCAm)
Mark Robson[1], Andrew Tutt[2], Judith Balmaña[3, 12], Bella Kaufman[4], Judy Garber[5], Charles Geyer[6], James Ford[7], Priyanka Sharma[8],
Mary Stuart[9], Helen Mann[9] and Peter A Fasching[10,11].
SABCS, publication number: OT1-1-04

BOOG 2014-04 / LORD
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study
Lotte E. Elshof a,b,c, Konstantinos Tryfonidis d, Leen Slaets e, A. Elise van Leeuwen-Stok f, Victoria P. Skinner a, Nicolas Dif g, Ruud M. Pijnappel h, Nina Bijker i, Emiel J.Th. Rutgers a, Jelle Wesseling b,j,⇑
European Journal of Cancer (2015) 51, 1497–1510

The LORD trial: A randomized, non-inferiority trial, between active surveillance versus standard treatment in patients with low risk ductal carcinoma in situ
Lotte E Elshof, Konstantinos Tryfonidis, Leen Slaets, A Elise van Leeuwen-Stok, Nicolas Dif, Victoria P Skinner, Claudette E Loo, Gonneke Warnars, Eveline Bleiker, Ruud M Pijnappel, Nina Bijker[5], Emiel JTh Rutgers and Jelle Wesseling,
Abstract SABCS 2014, Program Number: OT3-6-01

BOOG 2014-05 / INFLAME

Immune cell type fractions and gene expression in inflammatory breast cancer
Bense R, de Vries EGE, Fehrmann R, Schröder CP. Oral poster presentation by C.P. Schröder on July 10, 2016.
5th International Inflammatory Breast Cancer Conference, Harvard Medical School, Boston, U.S.A.

Patientenparticipatie

Patients' perceptions on breast cancer clinical trials
S. Tax., J.E. Elberse, C.A.C.M. Pittens, A.E. van Leeuwen-Stok, M. Schrieks, J.E.W. Broerse
Abstract ECCO 2013

How breast cancer patients value partaking in non-commercial clinical trials
C.A.C.M. Pittens, J.E. Elberse, A.E. Van Leeuwen-Stok, M. Jonker, J.E.W. Broerse
Submitted European Journal of Cancer Care, 2013

Patient involvement in breast cancer clinical trials: what do patients and professionals want?
C.A.C.M. Pittens, J.E. Elberse, A. E. Van Leeuwen-Stok, S. Tax, J.E.W. Broerse
Submitted Health Expectations, 2013

Wat wil de patient als het om onderzoek gaat? Interview met E. van der Wall,
Medische Oncologie dec 2012

Active Patient Involvement in Breast Cancer Clinical Trials, C.A.C.M. Pittens,
Presentatie 6th Clinical Forum Congress, 8-10 oktober 2012

Patients' Perceptions On Breast Cancer Clinical Trials
C.A.C.M. Pittens, J.E. Elberse, S. Tax, A.E. van Leeuwen-Stok, M. Schrieks, M. Jonker, J.E.W. Broerse
Abstract EBCC-8, 2012